Physician profile
Eric S Mitchell
NPI 1821077793
$7,968.76
in general payments reported to CMS, 2019-2025
39 companies · $1,417 in 2025
The $1,417 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,598 · 2020: $317 · 2021: $639 · 2022: $1,041 · 2023: $1,256 · 2024: $1,702 · 2025: $1,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,374.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $797.78 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $783.96 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $727.29 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| Janssen Pharmaceuticals, INC | $542.26 | 2019-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $509.61 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Astrazeneca Pharmaceuticals LP | $496.49 | 2019-2025 | Brilinta, Wainua |
| Amgen INC. | $440.05 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $423.92 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $368.57 | 2019-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $366.42 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $325.10 | 2019-2024 | Lifevest |
| Alnylam Pharmaceuticals INC. | $263.20 | 2022-2025 | Amvuttra, Onpattro |
| Novo Nordisk INC | $203.83 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Edwards Lifesciences Corporation | $186.50 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Esperion Therapeutics, INC. | $183.88 | 2021-2025 | Nexletol |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $146.67 | 2019 | |
| Abbott Laboratories | $136.40 | 2019-2024 | Cardiomems, Mitraclip |
| Inspire Medical Systems, INC. | $123.66 | 2024 | Inspire |
| Lexicon Pharmaceuticals, INC. | $113.36 | 2023-2024 | Inpefa |
| Boston Scientific Corporation | $109.90 | 2019-2025 | Bodyguardian, Watchman Flx |
| Cvrx, INC. | $68.79 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $60.65 | 2019-2024 | |
| Amarin Pharma, INC. | $57.30 | 2019 | |
| Irhythm Technologies, INC. | $53.25 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Kiniksa Pharmaceuticals, LTD. | $53.02 | 2022-2023 | Arcalyst |
| Astellas Pharma US INC | $50.76 | 2019-2022 | |
| Lantheus Medical Imaging, INC. | $44.91 | 2021-2022 | |
| Lundbeck LLC | $43.44 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $41.52 | 2024 | Arcalyst |
| Phathom Pharmaceuticals, INC. | $37.96 | 2024 | Voquezna |
| Heartflow, INC. | $31.54 | 2022-2024 | |
| Solventum Corporation | $30.36 | 2025 | Prevena |
| Kowa Pharmaceuticals America, INC. | $27.76 | 2021 | |
| Daiichi Sankyo INC. | $22.73 | 2022 | |
| Chiesi USA, INC. | $22.41 | 2025 | Juxtapid |
| Inari Medical, INC. | $21.94 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Akcea Therapeutics, INC. | $21.74 | 2019 | |
| Kls-Martin L.P. | $20.77 | 2025 | |
| Altathera Pharmaceuticals LLC | $9.06 | 2025 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.